PW Medtech Reports Interim Results with 77.7% Drop in Net Profit
Stock News
Aug 29
PW Medtech (01358) has released its interim results for the six months ended June 30, 2026, showing a significant decline in profitability. The group recorded revenue of RMB 394 million, representing a year-on-year decrease of 4.9%, while profit attributable to owners of the company amounted to RMB 14.692 million, down sharply by 77.74% compared to the same period last year.
Earnings per share stood at RMB 1.01 cents, with an interim dividend of HK 1.1 cents per share declared. The company attributed the revenue decline primarily to reduced sales in its infusion set business, which was partially offset by growth in its blood purification segment and regenerative medical biomaterials business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.